EUCTR2004-004963-32-AT进行中（未招募）不适用
Bevacizumab (Avastin®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC): a pilot trial - AVATACE-1
niv. Prof. Dr. Markus Peck-Radosavljevic0 个研究点目标入组 40 人开始时间: 2005年6月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Patients with histologically confirmed HCC not suitable for OLT or resection (>3 nodules, >5 cm diameter, vascular invasion, clinically significant portal hypertension, other contraindications against OLT)
- •?Child-Pugh Stage A and B
- •?Liver disease of any etiology
- •?Written informed consent (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures
- •?Patient must be able to comply with the protocol
- •?Age =18 years
- •?Women of childbearing potential must have a negative serum pregnancy test done 1 week prior to the administration of the study drug.
- •Fertile women and men of childbearing potential (<2 years after last menstruation in women) must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)
- •?Proteinuria at baseline:
- •Urine dipstick of proteinuria <2+. Patients discovered to have >?2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demonstrate ? 1 g of protein/24 hr.
- •?Haematology:
- •Absolute neutrophil count (ANC) > 1 x 109/L
- •Platelet count > 40 x 109/L
- •Haemoglobin > 9 g/dL (may be transfused to maintain or exceed this level)
- •Prothrombin time ? 40%
- •?Biochemistry:
- •Total bilirubin ? 5 mg/dL
- •Serum creatinine < 3.0 mg/dL
- •?Life expectancy of >3 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?extrahepatic tumor spread
- •?complete portal vein thrombosis (common trunk)
- •?Child-Pugh-Stage C
- •?Prior TACE or TAE
- •?Other experimental therapies for HCC
- •?Acute variceal bleeding within the last 2 weeks
- •?Large oesophageal varices (>5 mm diameter) without band ligation
- •?Past or current history (within the last 2 years prior to randomisation) of malignancies except for the indication under this study and curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix
- •?History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy or history of stroke within < 6 months), excluding hepatic encephalopathy
- •?Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study
- •?Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants for therapeutic purposes
- •?Chronic, daily treatment with aspirin (>325mg/day)
- •?Pregnancy (positive serum pregnancy test) or lactation
- •?Uncontrolled hypertension
- •?Serious, non-healing wound, ulcer, or bone fracture
- •?Patients with known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanized antibodies or to any excipients of Bevacizumab formulation; or to any other study drugs
- •?Currently or recent (within the 30 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study
- •?Clinically significant (i.e. active) cardiovascular disease for example cerebravascular accidents (= 6 months prior to randomisation), myocardial infarction (= 6 months prior to randomisation), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication
- •?Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications
研究者
相似试验
已完成
2 期
A Phase II Study of Bevacizumab (Avastin&reg;) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapyon-sq NSCLC with previously treatedJPRN-UMIN000007123Hiroshima University Hospital Respiratory medicine34
进行中（未招募）
不适用
Systemic Bevacizumab (Avastin®) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study) - BEAT-AMD-StudyAge related macular degeneration (AMD) patients with fibrovascular pigment epithelium detachment (PED), subfoveal choroidal neovascularisations (CNV) extending under the geometric center of the foveal avascular zone, and a central retinal thickness of at least 300 microns.EUCTR2005-001722-92-ATThe Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery30
进行中（未招募）
不适用
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000802-30-ITROCHE
已完成
不适用
Bevacizumab and vasoconstrictioelevated blood pressureHypertensie10057166NL-OMON33520niversitair Medisch Centrum Sint Radboud10
进行中（未招募）
不适用
BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - NDHEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)MedDRA version: 9.1Level: SOCClassification code 10005329EUCTR2010-020545-26-ITAZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE